Klotho Neurosciences (KLTO)announced that its Letter of Intent, or LoI, with Turn Biotechnologies was allowed to expire by the parties. Following careful evaluation, Klotho’s Board of Directors determined that the proposed transaction did not fit its long-term strategic plan. Instead, the Company will focus its resources on advancing its Klotho anti-aging protein research pipeline and development of treatments, where it sees the greatest opportunity to deliver value for patients and shareholders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences to acquire select assets from Turn Biotechnologies
- Klotho Neurosciences Faces Nasdaq Delisting Notice
- Klotho Neurosciences Delays Quarterly Report Filing
- Klotho Neurosciences Partners with AAVnerGene for Gene Therapy
- Klotho Neurosciences signs KLTO-202 manufacturing, development agreement